Webinar: Preclinical Pharmacokinetics (PK) and Pharmacodynamics (PD) Evaluation with Biocytogen

Webinar: Preclinical Pharmacokinetics (PK) and Pharmacodynamics (PD) Evaluation with Biocytogen

Our webinar “Preclinical Pharmacokinetics (PK) and Pharmacodynamics (PD) Evaluation with Biocytogen” was live on Sep 29, 2022 at 1PM EDT.

An understanding of the exposure-response relationship is critical to advancing the development of therapeutic candidates. Pharmacokinetics (PK),  the measure of drug absorption, distribution, and excretion over time, is one dimension of this relationship. Pharmacodynamics (PD), the biological effect exerted by the drug on the organism, is another. Join us to learn more about preclinical PK/PD evaluation with Biocytogen.

Among the topics we discussed are:

  • Defining pharmacokinetics/pharmacodynamics (PK/PD) and useful parameters to measure them
  • Biocytogen’s platforms suited for antibody PK/PD studies
  • Humanized mouse models useful for evaluation of PK/PD
  • In vivo case studies and examples
  • Your questions and concerns

About the Speaker & Panelists


John Charpentier, Ph.D, Scientific Content Specialist, Biocytogen Boston

A native of New England, John spent nearly a decade in laboratories focused on questions of fundamental T cell biology. After earning a Ph.D. in immunology from the University of Michigan, he joined Biocytogen in July 2021.  He has significant experience liaising between Biocytogen’s clients and scientific teams, and now works in a scientific communication role.



Zhaoxue (Luke) Yu, Ph.D.  Deputy General Manager & Global Head of Preclinical Pharmacology, Biocytogen Boston

Dr. Zhaoxue (Luke) Yu has more than 15 years of research and technical leadership experience in drug discovery and development for immune/autoimmune diseases, oncology, neurological diseases, ocular diseases and metabolic diseases, working with various therapeutic modalities including antibodies, biologics, small molecules, mRNAs, and AAVs. Prior to Biocytogen, Dr. Yu served as a pharmacology technical leader at Gemini Pharmaceuticals, Achillion Pharmaceuticals, and Alexion Pharmaceuticals. Dr. Yu has been a major contributor to multiple drug development programs from preclinical to clinical stages, some of which have subsequently obtained approvals by the FDA. Dr. Yu received his Ph.D in Neurobiology and M.D. in China. He has held postdoctoral research positions at institutions including Emory University, Yale University, and Harvard Boston Children’s Hospital.


Shivam Madaan, Ph.D. Senior Business Development Manager, Biocytogen Boston

Dr. Shivam Madaan began his training in pharmaceutical science and drug delivery 14 years ago at Amity University in India. He continued his studies in England, earning a M.Sc. in Drug Delivery and Ph.D. in Pharmaceutics from University College London, with his thesis research focusing on the development of implants for ophthalmic drug delivery. Dr. Madaan joined Biocytogen in 2020.


Jenna Frame, Ph.D.  Manager, Scientific Communications & Marketing, Biocytogen Boston

Dr. Jenna Frame has worked with mouse and zebrafish models in the hematology/oncology field for over 15 years at the University of Rochester and Harvard Medical School. At Biocytogen, Jenna helps provide researchers with the information they need to select quality animal models and other preclinical services to advance their scientific discoveries.



Watch the webinar recording here.



Back to top